Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Impaired cutaneous T-cell attracting chemokine elevation and adipose-derived stromal cell migration in a high-glucose environment cause poor diabetic wound healing.

Wang WT., Lee SS., Wang YC., Lai YW., Kuo YR., Tang Chen YB.

Prospective Study on Diabetic Foot, Chronic Wound, published in Kaohsiung J Med Sci (2018) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Kaohsiung J Med Sci (2018)
Country
China (Republic : 1949- )
Reported sample size
—
Source database
PubMed
PMID
30309481
PMCID
PMC12977103
DOI
10.1016/j.kjms.2018.05.002
Citations
12

Abstract (original English)

Diabetic wound care is a major health care concern. The major cause of non-healing of wounds in patients with diabetes mellitus (DM) patients mainly involves poor glycemic control, which hinders the migration of progenitor cells including mesenchymal stem cells to the wound site. In this study, we introduced adipose-derived stromal cells (ADSCs) into wound sites and demonstrated that the local transplantation of ADSCs accelerated DM-related wound healing. Furthermore, the migration ability of ADSCs, which diminishes in a high-glucose environment, was partially restored by the exogenous replenishment of the cutaneous T-cell attracting chemokine (CTACK/CCL27). Our findings suggest that CTACK is a potential novel therapeutic target in DM-related wound healing.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAnimalsBlood GlucoseCell MovementCells, CulturedChemokine CCL27Diabetes MellitusHumansMaleRats

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research